Scimera Bioscience, LLC – Trademark Portfolio
Entity Type: 16
Scimera Bioscience, LLC holds 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 20 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 2 Nice Classification classes. Currently, 9 trademarks are registered and 1 is pending. Notable registered marks include ASPREGA, VYZETRA, IMMUNEMD, PREXATOR, and SCIKRILL. The owner is based in Miami, FL.
4967 SW 7rth Ave
Miami, FL 33115
Showing of trademarks Trademarks
Trademark Classifications
Scimera Bioscience, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Frequently Asked Questions
How many trademarks does Scimera Bioscience, LLC have?
Scimera Bioscience, LLC has 21 U.S. trademarks filed with the USPTO. Of these, 9 registered, 1 pending, 4 abandoned, 7 cancelled.
What trademark classes does Scimera Bioscience, LLC file in?
Scimera Bioscience, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Scimera Bioscience, LLC's most well-known trademarks?
Scimera Bioscience, LLC's registered trademark portfolio includes well-known marks such as ASPREGA, VYZETRA, IMMUNEMD, PREXATOR, and SCIKRILL. These are among 9 currently registered trademarks in the portfolio.
What is Scimera Bioscience, LLC's trademark registration success rate?
Scimera Bioscience, LLC has a 45% trademark registration rate, with 9 out of 20 resolved applications resulting in successful registration. Currently, 1 application is pending review.